Germany

Boehringer Ingelheim GmbH

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

GERMANY Germany

Post An Enquiry

Virtual Booth

BIO IMPACT

Participation Not Confirmed

Update your events

Boehringer Ingelheim Announces Positive Results from Emperor-Reduced Phase III Trial of Empagliflozin in Adults with Heart Failure

Lead Product(s): Empagliflozin

Therapeutic Area: Cardiology/Vascular Diseases Product Name: BI10773

Highest Development Status: Phase III Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable August 29, 2020

Details:

The findings from the primary endpoint were consistent in subgroups with and without type 2 diabetes. Key secondary endpoint analyses from the trial demonstrated that empagliflozin reduced the relative risk of first and recurrent hospitalization for heart failure by 30%.

Bayer HealthCare

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

GERMANY Germany

Post An Enquiry

Virtual Booth

BIO IMPACT

Participation Not Confirmed

Update your events

Bayer Submits Vericiguat for Marketing Authorization in China for the Treatment of Chronic Heart Failure

Lead Product(s): Vericiguat

Therapeutic Area: Cardiology/Vascular Diseases Product Name: BAY 1021189

Highest Development Status: Phase III Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable August 28, 2020

Details:

Vericiguat is an investigational oral, once-daily, first-in-class soluble guanylate cyclase (sGC)-stimulator being developed to treat patients with symptomatic chronic heart failure with an ejection fraction less than 45%.

Boehringer Ingelheim GmbH

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

GERMANY Germany

Post An Enquiry

Virtual Booth

BIO IMPACT

Participation Not Confirmed

Update your events

Boehringer Ingelheim’s EMPEROR-Reduced phase II trial of empagliflozin in adults with heart failure meets primary endpoint

Lead Product(s): Empagliflozin

Therapeutic Area: Cardiology/Vascular Diseases Product Name: Jardiance

Highest Development Status: Phase III Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable July 31, 2020

Details:

Empagliflozin significantly reduced the risk of cardiovascular death or hospitalization for heart failure versus placebo in the EMPEROR-Reduced heart failure trial. The study evaluated adults with heart failure with reduced ejection fraction

Boehringer Ingelheim GmbH

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

GERMANY Germany

Post An Enquiry

Virtual Booth

BIO IMPACT

Participation Not Confirmed

Update your events

Boehringer Ingelheim's Empagliflozin Meets Primary Endpoint in Reducing Risk of Cardiovascular Death or Hospitalization

Lead Product(s): Empagliflozin

Therapeutic Area: Cardiology/Vascular Diseases Product Name: BI10773

Highest Development Status: Phase III Product Type: Small molecule

Partner/Sponsor/Collaborator: Eli Lilly

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable July 30, 2020

Details:

Empagliflozin significantly reduced the risk of cardiovascular death or hospitalization for heart failure versus placebo in the EMPEROR-Reduced heart failure trial. The study evaluated adults with heart failure with reduced ejection fraction.

Bayer HealthCare

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

GERMANY Germany

Post An Enquiry

Virtual Booth

BIO IMPACT

Participation Not Confirmed

Update your events

Bayer Extends Clinical Development Program for Finerenone with Phase III trial in Heart Failure and Preserved Ejection Fraction

Lead Product(s): Finerenone

Therapeutic Area: Cardiology/Vascular Diseases Product Name: Undisclosed

Highest Development Status: Phase III Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable June 15, 2020

Details:

FINEARTS-HF is the first large-scale, long-term study to investigate the non-steroidal, selective mineralocorticoid receptor antagonist finerenone on morbidity and mortality outcomes in a heart failure patient population.

Bayer HealthCare

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

GERMANY Germany

Post An Enquiry

Virtual Booth

BIO IMPACT

Participation Not Confirmed

Update your events

Bayer Submits Vericiguat for Marketing Authorization in the EU and Japan for the Treatment Of Chronic Heart Failure

Lead Product(s): Vericiguat

Therapeutic Area: Cardiology/Vascular Diseases Product Name: Undisclosed

Highest Development Status: Phase III Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable June 05, 2020

Details:

Regulatory submissions based on positive data from Phase III VICTORIA study recently published in the New England Journal of Medicine.

Find

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Product Type

Companies

Boehringer Ingelheim GmbH

Boehringer Ingelheim Announces Positive Results from Emperor-Reduced Phase III Trial of Empagliflozin in Adults with Heart Failure

Bayer HealthCare

Bayer Submits Vericiguat for Marketing Authorization in China for the Treatment of Chronic Heart Failure

Boehringer Ingelheim GmbH

Boehringer Ingelheim’s EMPEROR-Reduced phase II trial of empagliflozin in adults with heart failure meets primary endpoint

Boehringer Ingelheim GmbH

Boehringer Ingelheim's Empagliflozin Meets Primary Endpoint in Reducing Risk of Cardiovascular Death or Hospitalization

Bayer HealthCare

Bayer Extends Clinical Development Program for Finerenone with Phase III trial in Heart Failure and Preserved Ejection Fraction

Bayer HealthCare

Bayer Submits Vericiguat for Marketing Authorization in the EU and Japan for the Treatment Of Chronic Heart Failure